Literature DB >> 4425791

Blood levels and management of lithium treatment.

J L Crammer, R M Rosser, G Crane.   

Abstract

The limited value of plasma measurements in the management of treatment with lithium is discussed in the light of the mechanisms of its therapeutic actions and toxic effects.The plasma level of lithium usually rises twofold or threefold in the three to five hours after ingestion of each dose of delayed-release tablets and then gradually falls. The precise shape and height of the lithium curve depend on gastric emptying, which can be slowed with propantheline or speeded with metoclopramide. Depressed or demented patients may be irregular in taking their tablets and variable in food intake. Both the time of the blood test and this behaviour must be considered before changing the prescribed dose of lithium salt because of a laboratory result. A lithium tolerance curve may be a safer guide to treatment than single measures.Mild intermittent thirst is a common early side effect, and severe persistent thirst with polyuria is an uncommon later effect of daily intakes of at least 1,500 mg lithium carbonate. This diabetes insipidus is reversible, non-progressive, unrelated to plasma level, and distinct in attack from lithium-induced hypothyroidism, which may occur at low dosage but is also usually of late onset and reversible or treatable with thyroxine while lithium is continued. Obesity is another occasional effect of large doses. These side effects and the antimanic and prophylactic effects may have different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4425791      PMCID: PMC1611659          DOI: 10.1136/bmj.3.5932.650

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  14 in total

1.  Relationship between serum lithium level and clinical response in acute mania treated with lithium.

Authors:  R F Prien; E M Caffey; C J Klett
Journal:  Br J Psychiatry       Date:  1972-04       Impact factor: 9.319

2.  Hypothyroidism in patients treated with lithium: a review and two case reports.

Authors:  M J Crowe; G G Lloyd; S Bloch; R M Rosser
Journal:  Psychol Med       Date:  1973-08       Impact factor: 7.723

3.  Value of plasma-lithium monitoring.

Authors:  D E Fry; V Marks
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

4.  Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders.

Authors:  P C Baastrup; J C Poulsen; M Schou; K Thomsen; A Amdisen
Journal:  Lancet       Date:  1970-08-15       Impact factor: 79.321

Review 5.  Lithium in psychiatric therapy and prophylaxis.

Authors:  M Schou
Journal:  J Psychiatr Res       Date:  1968-06       Impact factor: 4.791

6.  Lithium, weight gain, and serum insulin in manic-depressive patients.

Authors:  E T Mellerup; H G Thomsen; N Bjorum; O J Rafaelsen
Journal:  Acta Psychiatr Scand       Date:  1972       Impact factor: 6.392

7.  Lithium-induced diabetes insipidus-like syndrome.

Authors:  B M Angrist; S Gershon; S J Levitan; A G Blumberg
Journal:  Compr Psychiatry       Date:  1970-03       Impact factor: 3.735

8.  Lithium absorption from sustained-release tablets (Duretter).

Authors:  A Amdisen; J Sjögren
Journal:  Acta Pharm Suec       Date:  1968-11

9.  Slow-release lithium carbonate.

Authors:  A Coppen; J E Bailey; S G White
Journal:  J Clin Pharmacol J New Drugs       Date:  1969 May-Jun

10.  Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption.

Authors:  J Nimmo; R C Heading; P Tothill; L F Prescott
Journal:  Br Med J       Date:  1973-03-10
View more
  12 in total

1.  Serum concentrations of lithium after three proprietary preparations of lithium carbonate (Priadel, Phasal and Camcolit).

Authors:  E H Bennie; A K Manzoor; A M Scott; G S Fell
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

2.  Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.

Authors:  K M Deppermann; H Lode; G Höffken; G Tschink; C Kalz; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

3.  A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters.

Authors:  J Gaillot; J L Steimer; A J Mallet; J J Thebault; A Bieder
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

4.  The effect of delayed gastric emptying and absorption on pharmacokinetic parameters of lithium.

Authors:  S E Bellibaş; I Tuğlular; A Kayali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 5.  Oral controlled release dosage forms. A review.

Authors:  P De Haan; C F Lerk
Journal:  Pharm Weekbl Sci       Date:  1984-04-27

Review 6.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

7.  Persistent nephrogenic diabetes insipidus, tubular proteinuria, aminoaciduria, and parathyroid hormone resistance following longterm lithium administration.

Authors:  W D Neithercut; R J Spooner; A Hendry; J H Dagg
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

Review 8.  Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes.

Authors:  R L Parsons
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

9.  Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage.

Authors:  D P Thornhill
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

10.  Lithium treatment for psychiatric disorders.

Authors:  B M Maletzky; J H Shore
Journal:  West J Med       Date:  1978-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.